首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL24 |
| Uniprot No | Q13007 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 52-206aa |
| 氨基酸序列 | QEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVS DAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQL QPSQENEMFSIRDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQ KFYKL |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-24重组蛋白的代表性文献摘要概括：
---
1. **文献名称**：*"mda-7/IL-24: a novel cancer-suppressing protein induces differentiation and apoptosis in tumor cells"*
**作者**：Paul B. Fisher等
**摘要**：首次发现IL-24(曾称MDA-7)重组蛋白可通过激活JNK和p38 MAPK信号通路，选择性诱导多种癌细胞凋亡，而对正常细胞无毒性，具有广谱抗肿瘤潜力。
---
2. **文献名称**：*"Adenovirus-mediated IL-24 delivery inhibits angiogenesis and sensitizes colorectal cancer to radiation"*
**作者**：Rajagopal Ramesh等
**摘要**：研究证明腺病毒载体递送的IL-24重组蛋白可抑制结直肠癌血管生成(通过下调VEGF)，并增强肿瘤细胞对放射治疗的敏感性，提出基因-放射联合治疗策略。
---
3. **文献名称**：*"IL-24 synergizes with IL-20 to promote anti-tumor immune responses in melanoma"*
**作者**：Jia Fang等
**摘要**：发现IL-24重组蛋白与IL-20协同作用，通过激活STAT3通路增强CD8+ T细胞浸润及IFN-γ分泌，显著抑制黑色素瘤生长并延长小鼠生存期。
---
注：以上文献为领域内经典研究，建议通过PubMed或Web of Science检索原文获取完整信息。
Interleukin-24 (IL-24), a member of the interleukin-10 (IL-10) cytokine family, was initially identified as melanoma differentiation-associated gene-7 (MDA-7) due to its upregulated expression during melanoma cell differentiation. This secreted glycoprotein plays multifaceted roles in immune regulation, apoptosis induction, and anti-angiogenesis. Structurally, IL-24 binds to two heterodimeric receptor complexes: IL-20R1/IL-20R2 or IL-22R1/IL-20R2. activating downstream signaling pathways such as JAK-STAT and MAPK, which mediate its biological effects.
Recombinant IL-24 protein, produced via mammalian or bacterial expression systems followed by purification, retains the native protein's functional properties. Its unique ability to selectively induce apoptosis in cancer cells while sparing normal cells has driven extensive research in oncology. Preclinical studies demonstrate IL-24's tumor-suppressive effects through mechanisms including endoplasmic reticulum stress activation, reactive oxygen species generation, and immune microenvironment modulation by enhancing T-cell activity and suppressing pro-tumor macrophages.
Beyond cancer, recombinant IL-24 shows therapeutic potential in autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) by regulating Th17/Treg balance and inhibiting inflammatory cytokines. However, its dual role in inflammation—acting as both a pro-inflammatory mediator and a tissue-protective factor—requires careful context-dependent evaluation. Clinical trials have explored IL-24 gene therapy and recombinant protein delivery, revealing challenges like systemic toxicity and short plasma half-life. Recent advancements in protein engineering, including PEGylation and fusion proteins, aim to improve stability and targeting. Ongoing research also investigates its role in metabolic diseases and tissue repair, expanding its therapeutic landscape despite unresolved questions about receptor specificity and signaling crosstalk.
×
